- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | New FDA head says no more pharma on advisory committees | ||
| Fr | GSK cements Blenrep comeback with MHRA approval | ||
| Fr | WHO (sans US) finishes draft pandemic preparedness agreement | ||
| Fr | Merida raises $121m for Graves drug, and other financings | ||
| Do | Lilly soars on first data for oral obesity candidate | ||
| Do | Tariffs 'could cancel out discounts with biosimilars' | ||
| Do | GSK reprimanded over "shocking error" in Omjjara info | ||
| Do | There's good news for RSV jab firms at delayed ACIP meeting | ||
| Do | Spruce Bio sows the seeds of its new future | ||
| Mi | FDA clears first migraine DTx from Click Therapeutics | ||
| Mi | Trump pledges drug price cuts - and action on 'pill penalty' | ||
| Mi | Trump pledges drug price cuts - and an end to 'pill penalty' | ||
| Mi | UK Biobank responds to fears over Chinese access to NHS data | ||
| Mi | J&J expecting $400m hit from tariffs in 2025 | ||
| Mi | After delay, Alzheimer's drug Leqembi gets green light in EU | ||
| Di | Norgine on a growth charge again with Theravia takeover deal | ||
| Di | Sanofi's 'daughter of Dupixent' heads to phase 3 in asthma | ||
| Di | Ironwood crashes down as FDA seeks new phase 3 trial | ||
| Di | Failed trial knocks back wider use of BMS' Camzyos | ||
| Di | US starts the clock ticking on pharma tariffs | ||
| Mo | Scancell taps into NHS matchmaking service for cancer trial | ||
| Mo | Pfizer's weight-loss aspirations are dealt a heavy blow | ||
| Mo | BMS gets another FDA okay for Opdivo/Yervoy combo | ||
| Mo | Why relying on AI outcome models may not be a good idea | ||
| Mo | Approval moves Columvi earlier in DLBCL treatment pathway |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
